Prostate cancer is the most common form of cancer among men in England, with cases surging by 25 per cent between 2019 and 2023, according to NHS data. It’s also the second-deadliest form of the ...

THIS YEAR, IT’S estimated that nearly 300,000 new prostate cancer cases will be diagnosed. While there’s no single test to detect prostate cancer, doctors commonly use the prostate-specific antigen ...

A meta-analysis explores whether there’s a survival benefit to adding hormone therapy to postoperative radiation for patients with low PSA levels.

A single PSA test at midlife may identify men with a low risk of prostate cancer for up to 20 years, supporting longer screening intervals. Men with a low baseline PSA level at midlife have a low risk ...

DEAR DR. ROACH: I am a 68-year old male in good health who exercises regularly, doesn’t take any medications, and doesn’t have a family history of prostate cancer. During my most recent yearly ...

NEW YORK (Reuters Health) - On average, men's levels of prostate-specific antigen (PSA) decrease as their body mass index (BMI) rises, a new study shows. PSA is a marker for prostate cancer risk when ...

Hormone therapy initiation depends on disease extent; some agents avoid testosterone flare, allowing ADT without Casodex in certain cases. Active surveillance is increasingly chosen for favorable ...

Achieving a PSA nadir of less than 0.2 ng/mL is needed for optimal mCSPC outcomes. For real-world patients with metastatic castration-sensitive prostate cancer (mCSPC), reaching a PSA nadir less than ...

In a population-based cohort study, a single prostate-specific antigen (PSA) measurement in men aged 45-70 years effectively identified individuals with low risk for cancer. Men with PSA levels < 1.00 ...

Prostate cancer is the most common cancer in Australia, with about 26,000 men diagnosed per year. The majority (more than 85%) are aged over 60. Subscribe to our newsletter for the latest sci-tech ...